Search
for
Sort by
Research 121–150 of 1000+
- 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia
- 5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men
- Reply to Effectiveness of dutasteride in a large series of patients with frontal fibrosing alopecia in real clinical practice
- Impact of anti-androgen therapies on COVID-19 susceptibility: a case-control study in male population from two COVID-19 regional centers of Lombardy (Italy)
- Risk of Depression after 5 Alpha Reductase Inhibitor Medication: Meta-Analysis
- 5-alpha Reductase inhibitors and risk of male breast cancer: a systematic review and meta-analysis
- Association Between 5-Alpha Reductase Inhibitor Use and The Risk of Depression: A Meta-Analysis.
- Sexual, physical, and overall adverse effects in patients treated with 5α-reductase inhibitors: a systematic review and meta-analysis
- Response to “Reply to effectiveness of dutasteride in a large series of patients with FFA in real clinical practice”
- Effects of 5-alpha reductase inhibitors
- Five-Alpha Reductase Inhibitor and Breast Cancer Risk in Men: A Systematic Review
- MP89-08 POST-FINASTERIDE SYNDROME: REAL OR IMAGINED?
- Finasteride versus dutasteride: a real-world economic evaluation.
- Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese
- Change in hair growth-related gene expression profile in human isolated hair follicles induced by 5-alpha reductase inhibitors – dutasteride and finasteride – in the presence of testosterone
- 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study
- Analysis of Data From Breast Diseases Treated With 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia
- Further research needed if finasteride is to become standard of care for frontal fibrosing alopecia (FFA)
- 5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Do Alpha-Blockers and 5-Alpha Reductase Inhibitors Increase Dementia Risk? A Network Meta-analysis
- The Association Between 5α-Reductase Inhibitors and the Presence of Subsequent Dry Eye Disease in Androgenetic Alopecia: A TriNetX Database Study
- Treatment of Alopecia with New Approaches: An Updated Review
- The Efficacy of Oral Finasteride and Dutasteride in the Treatment of Female Pattern Hair Loss and Frontal Fibrosing Alopecia in Women: A Scoping Review
- 61537 No Increased Risk of Breast or Gynecologic Cancers in Women with 5α-Reductase Inhibitor Exposure for Female Pattern Hair Loss: A Population-Based Propensity Score-Matched Cohort Study
- Effect of 5-alpha reductase inhibitors in animal models of Parkinson’s disease
- Risk of Estrogen-Driven Malignancies in Females on 5-alpha Reductase Inhibitors
- Impact of finasteride and dutasteride in beard thickness in men with androgenetic alopecia: a 453-patient retrospective trial
- LB891 Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
- Risk of age-related macular degeneration in men receiving 5α-reductase inhibitors: a population-based cohort study